mRNAMC38

mRNAMC38 is a preclinical mRNA-based cancer vaccine specifically engineered to target the MC38 murine colon adenocarcinoma cell line. The vaccine typically comprises synthetic mRNA sequences encoding tumor-specific neoantigens, such as the p15E envelope protein, which are encapsulated in lipid nanoparticles (LNPs) for efficient intracellular delivery. Upon administration, the mRNA is translated by host cells, leading to the presentation of these antigens on MHC class I molecules and the subsequent activation of antigen-specific CD8+ T cells. This mechanism induces a targeted immune response capable of inhibiting tumor growth and providing long-term immunological memory in syngeneic mouse models. mRNAMC38 serves as a critical tool for evaluating the efficacy of mRNA delivery systems and the potency of neoantigen-based immunotherapy.

Other names

MC38 mRNA vaccineMC-38 mRNA vaccineMC 38 mRNA vaccinemRNA-based MC38 cancer vaccine